Cancer Immunotherapy Market Size, Share, Analysis and Forecast Report to 2020

GLOBAL & USA CANCER IMMUNOTHERAPY

MARKET ANALYSIS TO 2020: Antibody Drug Conjugates

(ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines,

Cytokines, Interferons, Chimeric Antigen Receptor (CAR)

T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells,

Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO

Inhibitors

Prior to the launching of Yervoy, the five-year survival rate for patients with early stage

melanoma was 98%; but the five-year survival rate for late-stage melanoma was just 16%.

Yervoy has been reported to have a survival rate of 25% when tested alone. When tested as part

of a combination therapy treatment with Bristol’ s nivolumab, the two-year survival rates rose to

88% for patients with late-stage cancer. Increase in patient survival rates brought about by cancer

immunotherapy treatment is similar to that seen when bone marrow transplantation changed our

conception on how blood cancer was treated.

Therefore, it is no wonder that in 2013, most science journals hailed cancer immunotherapy as

the breakthrough treatment of the year. Conceivably, what makes advancements in cancer

immunotherapy research even more dramatic is the fact it has the potential to treat a wide range

of tumor types. If the present trends continue, cancer immunotherapy drugs will have a market

value of about $80 billion in 2020. A single drug, Bristol-Myers Squibb’ s Yervoy, for example

has earned revenues of about $960 million in 2013 and it is expected to have a market value of

$1,775.2 million in 2020.

To know more about this report, Click here:

https://marketreportscenter.com/reports/328787/global-usa-cancer-immunotherapymarket-analysis-to-2020

Recently, a new class of anti-cancer agents called checkpoint inhibitors has hit the market. In the

first week of September 2014, Bristol-Myers Squibb and Ono Pharmaceutical launched their PD1 (programmed cell death-1) inhibitor Opdivo (nivolumab) in Japan for unresectable melanoma.

Later, Merck got FDA...